Marco Fornaro, Roberto Caporali, Martina Biggioggero, Serena Bugatti, Ludovico De Stefano, Alberto Cauli, Mattia Congia, Fabrizio Conti, Maria Sole Chimenti, Chiara Bazzani, Simone Perniola, Fabiola Atzeni, Giovanni Lapadula, Gianfranco Ferraccioli, Florenzo Iannone
OBJECTIVES: The aim of this study was to evaluate the effectiveness and safety profile of filgotinib, a JAK1 preferential inhibitor, in rheumatoid arthritis (RA) patients included in Italian GISEA (Group for the Study of Early Arthritis) registry. METHODS: Data from RA patients treated with filgotinib, recorded in the GISEA registry, were analysed. Disease activity scores and patient-reported outcomes (PROs) were assessed at baseline, as well as during 12-month follow-up...
April 17, 2024: Clinical and Experimental Rheumatology